Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 23, 2026Expert Review of Anti-infective Therapy

Impact of nirmatrelvir/ritonavir on the risk of long COVID in outpatients: a systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

CCC. CucunawangsihAAArif Nur Muhammad AnsoriAVAkhil Deepak Vatvani

Discussion

Loading...

Member takes

Overview

Systematic review shows nirmatrelvir/ritonavir may reduce long COVID risk in outpatients, indicating varying symptom benefits.

Key Points

  • This research aims to determine the effectiveness of nirmatrelvir/ritonavir in reducing the risk of long COVID in outpatient settings.
  • Conducted a systematic review and meta-analysis
  • Included studies assessing outpatient treatment with nirmatrelvir/ritonavir
  • Evaluated multiple symptom categories for long COVID
  • Nirmatrelvir/ritonavir may reduce the risk of developing long COVID
  • Benefits vary across different symptom categories

Cite This Study

Cucunawangsih et al. (2026) studied this question.

synapsesocial.com/papers/699bee1c1c6c6bad5397fcc9https://doi.org/10.1080/14787210.2026.2636175
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Association of nirmatrelvir–ritonavir with post-acute sequelae and mortality in patients admitted to hospital with COVID-19: a retrospective cohort study2024 · 17 citations
  2. 2Real-world application of nirmatrelvir/ritonavir in hospitalized COVID-19 patients with onset of symptoms beyond 5 days: a comparative study2024 · 3 citations
  3. 3Effectiveness of Nirmatrelvir/Ritonavir for Outpatients in the Era of Omicron, Vaccination, and Previous Infection: A Meta-analysis2026
  4. 4Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia2024
  5. 5Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-192024 · 145 citations